TGI
NRIX icon

TRV GP III’s Nurix Therapeutics NRIX Stock Holding History

TRV GP III’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-1,922,549
Closed -$24.4M – 7
2022
Q2 		$24.4M Hold
1,922,549
– – 9.96% 4
2022
Q1 		$26.9M Sell
1,922,549
-500,000
-21% -$8.88M 7.31% 5
2021
Q4 		$70.1M Hold
2,422,549
– – 17.55% 3
2021
Q3 		$72.6M Sell
2,422,549
-1,000,000
-29% -$30.9M 13.78% 4
2021
Q2 		$90.8M Sell
3,422,549
-1,085,784
-24% -$31.9M 15.85% 3
2021
Q1 		$140M Sell
4,508,333
-914,216
-17% -$34.6M 17.73% 3
2020
Q4 		$178M Hold
5,422,549
– – 15.31% 3
2020
Q3 		$189M Buy
+5,422,549
New +$137M 15.9% 3

Other funds holding NRIX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

TRV GP III's NRIX Position: Q3 2022 in Review

TRV GP III sold out of Nurix Therapeutics (NRIX) in Q3 2022, closing a stake of 1,922,549 shares — an estimated $24.4M sold.

TRV GP III first reported a position in NRIX in Q3 2020 and held it in 8 quarters. The position peaked at $189M in Q3 2020. 118 funds tracked by Wall St. Rank hold NRIX as of Q3 2022.

  • TRV GP III reported no remaining Nurix Therapeutics position as of Q3 2022 after selling out during the quarter.
  • TRV GP III sold 1,922,549 Nurix Therapeutics shares in Q3 2022, an estimated $24.4M.
  • TRV GP III first reported a position in Nurix Therapeutics in Q3 2020 and held it in 8 quarters.
  • TRV GP III's Nurix Therapeutics position peaked at $189M in Q3 2020.
  • 118 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q3 2022.

Based on TRV GP III's 13F filing for Q3 2022, filed 3 Nov 2022.